Fig. 2: Change in ALT and AST from baseline up to end-of-treatment.

a, ALT Parts A + B. b, ALT Part C. c, AST Parts A + B. d, AST Part C. *P < 0.05, **P < 0.01, ***P < 0.001 versus placebo. Data are presented as LS mean change (s.e.) with two-sided unadjusted P values from repeated measures ANCOVA.